Treatment progress of chemotherapy induced thrombocytopenia
10.11904/j.issn.1002-3070.2016.02.020
- VernacularTitle:化疗所致血小板减少症治疗的研究进展
- Author:
Guoqiang SUN
;
Lichun SUN
- Publication Type:Journal Article
- Keywords:
Chemotherapy;
Thrombocytopenia;
Treatment
- From:
Practical Oncology Journal
2016;30(2):184-188
- CountryChina
- Language:Chinese
-
Abstract:
Chemotherapy induced thrombocytopenia( CIT) is a major dose-limiting hematologic toxicity with cancer patients.Aside from bleeding risk, thrombocytopenia limits chemotherapy doses and frequencies. While platelet transfusion is remain the elementary method for CIT,administration of platelet growth factors,such as recombinant human interleukin-11(rhIL-11),recombinant human thrombopoietin(rhTPO)and thrombopoie-tin receptor agonist(TPO-RA),are convenient and effective platelet-support strategies for patients receiving myelosuppressive chemotherapy.In addition,other cytokines and proximal splenic artery embolization( PSAE) are expected to be new clinical therapies.In this review,we summarize the existing data and approaches in the treat-ment progress of CIT.
